#United States #New York #ARS Pharmaceuticals #SPRY #Eric Karas

Overview of the Class Action Lawsuit Against ARS Pharmaceuticals

ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is currently facing a class action lawsuit, and investors should take heed of the details surrounding this case. The lead plaintiff deadline is set for October 5, 2026, meaning that affected investors must act swiftly to become involved. The class action has been initiated by Levi & Korsinsky, LLP, a well-known firm in securities litigation, indicating that there may be significant implications for stakeholders of ARS Pharmaceuticals.

Identifying the Claims

The lawsuit focuses on claims made against Eric Karas, the Chief Commercial Officer (CCO) of ARS Pharmaceuticals, who has been named as a defendant. It alleges that the company, along with its executives, misled investors regarding the timeline for the expanded coverage of neffy, a needle-free epinephrine nasal spray, under CVS Caremark. The complaint suggests that investors were led to believe that the rollout of coverage was progressing, which later turned out to be inaccurate.

Context of the Allegations

On March 9, 2026, during an earnings call, Karas assured investors that the company was focusing on securing coverage with major payers, including CVS Caremark, and claimed that approximately 93% of overall commercial coverage was in place. Just a few months later, on May 15, he stated that the approval process was in its final stages. However, this optimism was soon undermined when, on June 24, 2026, the company disclosed a lack of new commercial formulary additions that had been anticipated for the upcoming July 1, 2026 cycle. This announcement was a significant setback, as it meant that the expected expanded coverage would not occur. The subsequent drop in stock prices—by an alarming 23.9%—left many investors feeling betrayed.

Implications for Investors

For those who bought shares in ARS Pharmaceuticals between March 9, 2026, and June 24, 2026, allegations suggest they may have been misled and might be eligible for recovery of losses. The lawsuit points out that anyone who suffered financial damage due to the alleged misrepresentations may wish to pursue legal action. Therefore, investors who are considering their options should gather relevant brokerage records, including dates of purchase, share quantities, and prices paid.

Next Steps for Interested Investors

To ensure eligibility as a lead plaintiff, individuals must submit their information to Levi & Korsinsky by the October 5, 2026 deadline. Even if investors no longer hold their shares, they may still recover losses if they purchased during the class period. It's important for potential plaintiffs to act quickly and seek guidance on how to proceed. They can reach out for a no-obligation consultation to assess their situation and understand their options moving forward.

Conclusion

This developing situation around ARS Pharmaceuticals serves as a reminder of the essential due diligence required when investing in publicly traded companies. Misrepresentations can lead to significant financial ramifications, and understanding legal rights in these situations can be crucial for safeguarding investments. Stakeholders are advised to stay informed and participate actively in seeking recovery if they feel wronged by the company's actions.

For more inquiries or assistance, investors may contact Joseph E. Levi, Esq. at [contact email] or call the firm at (212) 363-7500.

About Levi & Korsinsky, LLP

Levi & Korsinsky has established a strong reputation over the past two decades for their success in securing financial recovery for shareholders. Experience matters when navigating the complexities of securities litigation, and a team like theirs can guide affected investors through this challenging process.